Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada. Show more

Location: The Canadian Venture Building, Toronto, ON, M5C 1P1, Canada | Website: https://revivethera.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

6.118M

52 Wk Range

$0.01 - $0.03

Previous Close

$0.01

Open

$0.02

Volume

15,501

Day Range

$0.01 - $0.02

Enterprise Value

6.088M

Cash

46.42K

Avg Qtr Burn

-259.5K

Insider Ownership

1.51%

Institutional Own.

0.00%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.